摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-溴-5-乙基噻唑-4-羧酸甲酯 | 81569-46-2

中文名称
2-溴-5-乙基噻唑-4-羧酸甲酯
中文别名
2-溴-5-乙基-噻唑-4-甲酸甲酯
英文名称
methyl 2-bromo-5-ethylthiazole-4-carboxylate
英文别名
methyl 2-bromo-5-ethyl-1,3-thiazole-4-carboxylate
2-溴-5-乙基噻唑-4-羧酸甲酯化学式
CAS
81569-46-2
化学式
C7H8BrNO2S
mdl
——
分子量
250.116
InChiKey
YVZQQKSGEFCXLI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    98-100 °C(Press: 0.25 Torr)
  • 密度:
    1.572

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    67.4
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934100090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:841bd76fdab680c7080109811dc575b4
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Methyl 2-bromo-5-ethylthiazole-4-carboxylate
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 2-bromo-5-ethylthiazole-4-carboxylate
CAS number: 81569-46-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8BrNO2S
Molecular weight: 250.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-溴-5-乙基噻唑-4-羧酸甲酯(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride锂硼氢三甲基铝 、 cesium fluoride 作用下, 以 四氢呋喃1,4-二氧六环二氯甲烷甲苯 为溶剂, 反应 64.5h, 生成 (S)-N-(2-chloro-4-methylpyridin-3-yl)-4-(5-ethyl-4-(hydroxymethyl)thiazol-2-yl)-5-fluoro-2-((1,1,1-trifluoropropan-2-yl)oxy)benzamide
    参考文献:
    名称:
    [EN] BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS
    [FR] INHIBITEURS DE LA DIHYDROOROTATE DÉSHYDROGÉNASE BI-ARYLE
    摘要:
    披露了用于治疗受DHODH调制影响的疾病、失调或医疗条件的化合物、组合物和方法。这些化合物由以下式I表示:式I其中R1、R2、R3和Q在此定义。
    公开号:
    WO2021070132A1
  • 作为产物:
    参考文献:
    名称:
    NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS
    摘要:
    提供以下式(1)所代表的含氮杂环化合物。当这些化合物或其盐被给予人类或动物时,它们具有强烈的EP1拮抗活性,并且它们作为预防或治疗过度活动膀胱的药物的有效成分是有用的,例如。此外,它们作为预防或治疗包括频繁排尿、尿急和尿失禁等症状的药物的有效成分是有用的。
    公开号:
    US20100029690A1
点击查看最新优质反应信息

文献信息

  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS
    申请人:ATOBE Masakazu
    公开号:US20100029690A1
    公开(公告)日:2010-02-04
    Nitrogen-containing heterocyclic compounds represented by the following Formula (1) are provided. The compounds or salts thereof have a strong EP1 antagonistic activity when they are administered to a human or an animal, and they are useful as an effective component of a pharmaceutical agent for prophylaxis and/or treatment of an overactive bladder, for example. Furthermore, they are useful as an effective component of a pharmaceutical agent for the prophylaxis and/or treatment of symptoms including frequent urination, urinary urgency and urinary incontinence.
    提供以下式(1)所代表的含氮杂环化合物。当这些化合物或其盐被给予人类或动物时,它们具有强烈的EP1拮抗活性,并且它们作为预防或治疗过度活动膀胱的药物的有效成分是有用的,例如。此外,它们作为预防或治疗包括频繁排尿、尿急和尿失禁等症状的药物的有效成分是有用的。
  • N-acylsulfonamide apoptosis promoters
    申请人:——
    公开号:US20020055631A1
    公开(公告)日:2002-05-09
    N-Benzoyl arylsulfonamides having the formula 1 are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.
    N-苯甲酰芳基磺胺酰胺具有以下化学式,是BCL-Xl抑制剂,有助于促进细胞凋亡。还公开了BCL-Xl抑制组合物和在哺乳动物中促进细胞凋亡的方法。
  • N-Acylsulfonamide apoptosis promoters
    申请人:——
    公开号:US20020086887A1
    公开(公告)日:2002-07-04
    N-Benzoyl arylsulfonamides having the formula 1 Are BCL-X1 inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-X1 inhibiting compositions and methods of promoting apoptosis in a mammal.
    N-苯甲酰芳基磺胺酰胺具有以下化学式,是BCL-X1抑制剂,有助于促进细胞凋亡。还公开了BCL-X1抑制组合物和在哺乳动物中促进细胞凋亡的方法。
  • [EN] ALKYNYL ALCOHOLS AND METHODS OF USE<br/>[FR] ALCOOLS D'ALCYNYLE ET LEURS PROCÉDÉS D'UTILISATION
    申请人:HOFFMANN LA ROCHE
    公开号:WO2016135163A1
    公开(公告)日:2016-09-01
    The invention relates to compounds of formula (I), wherein Q, A1-A8, R4 and R5 are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
    本发明涉及公式(I)的化合物,其中Q,A1-A8,R4和R5如本文所述。公式(I)的化合物及其药物组合物可用于治疗在NF-kB信号过度激活的疾病和失调。
  • CYANOTRIAZOLE COMPOUNDS
    申请人:OTSUKA PHARMACEUTICAL CO., LTD.
    公开号:US20160229816A1
    公开(公告)日:2016-08-11
    This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.
    本发明涉及一种由式(1)表示的氰基三唑化合物,其中每个符号在规范中有定义,或其盐。该化合物或其盐刺激柠檬酸循环活性和/或改善高血糖症的副作用较小,安全性优异,因此,它对于治疗和/或预防柠檬酸循环激活和/或改善高血糖症具有预防和/或治疗作用的疾病或疾病具有用处,例如糖尿病、糖耐量受损、胰岛素抵抗、糖尿病并发症、肥胖症、血脂异常、脂肪肝、动脉粥样硬化和/或心血管疾病,以及那些从刺激能量消耗中受益的疾病或疾病。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺